c-Kit(肥大/干细胞生长因子受体)
C-kit is a type of receptor tyrosine kinase and a type of tumor marker, also called CD117 and stem cell factor receptor.
- Cat.No. 产品名称 Information
-
GC69050
Elenestinib
Elenestinib (BLU-263 ) 是一种有效的口服活性酪氨酸激酶 (b>tyrosine kinase) 抑制剂。Elenestinib 具有研究系统性肥大细胞增多症(SM)的潜力。
-
GC68727
Barzolvolimab
Barzolvolimab (CDX 0159) 是一种人源化抗 KIT IgG1 单克隆抗体。Barzolvolimab 特异性并有效抑制 KIT 的激活。Barzolvolimab 可以减少慢性诱导性荨麻疹的皮肤肥大细胞和疾病活动。
-
GC25313
CS-2660 (JNJ-38158471)
CS-2660 (JNJ-38158471) is a well tolerated, orally available, highly selective VEGFR-2 inhibitor with IC50 of 40 nM. CS-2660 (JNJ-38158471) also inhibits closely related tyrosine kinases such as RET (c-RET) and Kit (c-Kit) with IC50 of 180 nM and 500 nM,while it has no significant activity (>1 microM) against VEGFR-1 and VEGFR-3.
-
GC65948
c-Kit-IN-5-1
AMG-25 is a novel potent and selective c-Kit inhibitor.
-
GC64810
Bezuclastinib
Bezuclastinib (CGT9486; PLX 9486) 是一种有效的 c-kit 和c-kit D816V 抑制剂,0.0001
-
GC62314
M4205
M4205 是一种 c-KIT 抑制剂,对 c-KIT V654A 作用的 IC50 值为 10 nM。M4205 对外显子 11, 13, 17 突变型 c-KIT 具有很高的活性。
-
GC62145
Chiauranib
Chiauranib (CS2164) selectively inhibits multiple kinase targets aurora B kinase (AURKB), colony-stimulating factor 1 receptor (CSF1R), and vascular endothelial growth factor receptor (VEGFR)/platelet-derived growth factor receptor (PDGFR)/c-Kit , thereby inhibiting the rapid proliferation of tumor cells, enhancing the antitumor immunity, and inhibiting tumor angiogenesis, to achieve the anti-tumor efficacy.
-
GC60930
Imatinib D4
ImatinibD4(STI571D4)是Imatinib(STI571)的氘代物。Imatinib是一种口服生物可用的酪氨酸激酶抑制剂,可选择性抑制BCR/ABL,v-Abl,PDGFR,c-kit激酶活性。
-
GC39612
Imatinib D8
Imatinib D8 (STI571 D8) 是 Imatinib (STI571) 的氘代物。Imatinib 是一种口服生物可用的酪氨酸激酶抑制剂,可选择性抑制 BCR/ABL,v-Abl,PDGFR,c-kit 激酶活性。
-
GC38853
Tandutinib hydrochloride
An antagonist of PDGFRβ, FLT3, and c-
Kit -
GC38757
c-Kit-IN-3 hydrochloride
c-Kit-IN-3 hydrochloride (Compound 18) 是一种有效的 c-KIT 激酶抑制剂,对 BaF3-tel-c-KIT (IC50 为 4 nM) 和广泛的耐药性突变体 (对 BaF3-tel-c-KIT-T670I 的 IC50 为 8 nM),具有很高的生物利用度。
-
GC38756
c-Kit-IN-3 D-tartrate
c-Kit-IN-3 (D-tartrate) (Compound 18) 是一种有效的 c-KIT kinase 激酶抑制剂,对 BaF3-tel-c-KIT (IC50 为 4 nM) 和广泛的耐药性突变体 (对 BaF3-tel-c-KIT-T670I 的IC50为 8 nM),具有很高的生物利用度。
-
GC38595
c-Kit-IN-3
c-Kit-IN-3 (Compound 18) 是一种有效的 c-KIT 激酶抑制剂,IC50 为 4 nM。c-Kit-IN-3 在生化分析中显示出对 c-KIT 激酶和多种耐药突变体的强大效价,并具有很高的生物利用度。
-
GC37808
Toceranib phosphate
A multi-targeted receptor tyrosine kinase inhibitor
-
GC37538
Ripretinib
A KIT and PDGFRα inhibitor
-
GC36546
Masitinib mesylate
An inhibitor of c-Kit
-
GC36438
Lenvatinib mesylate
An inhibitor of VEGFR2 and VEGFR3
-
GC35705
c-Kit-IN-2
c-Kit-IN-2 是一种 c-KIT 抑制剂,IC50 值为 82 nM,对三种 GIST 细胞系 GIST882、GIST430 和 GIST48 均有较好的抗增殖活性,GI50 值分别为 3、1 和 2 nM。
-
GC35685
CHMFL-KIT-033
CHMFL-KIT-033 是一种有效、可选择性的 c-KIT T670I 突变型的抑制剂, IC50 值为 0.045 μM。用于胃肠道间质瘤 (GISTs) 的治疗。
-
GC35682
CHMFL-ABL/KIT-155
CHMFL-ABL/KIT-155 (CHMFL-ABL-KIT-155; compound 34) 是一种高效的,具有口服活性的 type II ABL/c-KIT 双激酶抑制剂 (IC50 分别为 46 nM 和 75 nM),对 BLK (IC50=81 nM), CSF1R (IC50=227 nM), DDR1 (IC50=116 nM), DDR2 (IC50=325 nM), LCK (IC50=12 nM), PDGFRβ (IC50=80 nM) 激酶也具有明显的抑制活性。CHMFL-ABL/KIT-155 (CHMFL-ABL-KIT-155) 阻止细胞周期进展和诱导细胞凋亡。
-
GC34708
Pexidartinib hydrochloride
A multi-targeted receptor tyrosine kinase inhibitor
-
GC33362
Amuvatinib hydrochloride (MP470 hydrochloride)
A multi-targeted RTK inhibitor
-
GC33246
AZD3229 Tosylate
An inhibitor of c-Kit-driven cell proliferation
-
GC33027
AZD3229
An inhibitor of c-Kit-driven cell proliferation
-
GC32867
Flumatinib (HHGV678)
A Bcr-Abl inhibitor
-
GC19332
Sitravatinib
A multi-kinase inhibitor
-
GC19074
Avapritinib
A dual inhibitor of KIT and PDGFRα mutant kinases
-
GC18167
AC710
A PDGFR family kinase inhibitor
-
GC13961
ISCK03
An inhibitor of SCF/c-kit signaling
-
GC12222
Pexidartinib (PLX3397)
A multi-targeted receptor tyrosine kinase inhibitor
-
GC17959
AZD2932
A multi-kinase inhibitor
-
GC15075
PLX647
A dual inhibitor of FMS and KIT
-
GC10314
Imatinib (STI571)
伊马替尼 (STI571) (STI571) 是一种口服生物可利用的酪氨酸激酶抑制剂,可选择性抑制 BCR/ABL、v-Abl、PDGFR 和 c-kit 激酶活性。伊马替尼 (STI571) (STI571) 通过在 ATP 结合位点附近结合而起作用,将其锁定在封闭或自我抑制的构象中,从而半竞争性地抑制蛋白质的酶活性。伊马替尼 (STI571) 也是 SARS-CoV 和 MERS-CoV 的抑制剂。
-
GC14292
Apatinib Mesylate
A selective VEGFR2 inhibitor
-
GC15254
Tandutinib (MLN518)
An antagonist of PDGFRβ, FLT3, and c-Kit
-
GC13914
Flumatinib mesylate
A Bcr-Abl inhibitor
-
GC11763
Telatinib (BAY 57-9352)
A multi-kinase inhibitor
-
GC12730
Pazopanib Hydrochloride
A multi-kinase inhibitor
-
GC11336
Motesanib Diphosphate (AMG-706)
A multikinase inhibitor
-
GC15454
Lenvatinib (E7080)
An inhibitor of VEGFR2 and VEGFR3
-
GC14957
OSI-930
A dual inhibitor of Kit and VEGFR2
-
GC15779
Cabozantinib (XL184, BMS-907351)
A VEGFR2 inhibitor
-
GC13547
Dovitinib (TKI-258, CHIR-258)
A multi-kinase inhibitor
-
GC11759
Imatinib Mesylate (STI571)
An inhibitor of c-Abl, Bcr-Abl, PDGFR, and c-Kit
-
GC17958
Linifanib (ABT-869)
A dual VEGFR and PDGFR family kinase inhibitor
-
GC13410
Masitinib (AB1010)
An inhibitor of c-Kit
-
GC10719
Toceranib
A multi-targeted receptor tyrosine kinase inhibitor
-
GC14315
SU14813 maleate
A dual VEGFR and PDGFR family kinase inhibitor
-
GC14733
SU14813
A dual VEGFR and PDGFR family kinase inhibitor
-
GC13012
Motesanib
Motesanib (AMG 706) 是一种有效的 ATP 竞争性 VEGFR1/2/3 抑制剂,IC50 分别为 2 nM/3 nM/6 nM,对 Kit 具有相似的活性,对 VEGFR 的选择性比对 VEGFR 的选择性高约 10 倍PDGFR 和 Ret。